LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

By LabMedica International staff writers
Posted on 28 Mar 2023
Print article
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research Institute (IGTP, Barcelona, Spain) have been working on developing and validating an assay that can detect hepatitis C virus RNA using dried blood spot (DBS) samples, simplifying its diagnosis. The use of these minimally invasive samples can make it easier to diagnose hepatitis C for vulnerable populations like those who inject drugs. While the new test has shown good clinical performance as a diagnostic tool for detecting HCV RNA before treatment in previous studies by the research group, its efficacy as a test for cure or for detecting reinfection after treatment using DBS samples had not yet been evaluated.

People who inject drugs are at risk of HCV reinfection, which must be treated promptly to prevent further transmission of the virus. However, detecting the virus in DBS samples can be difficult during early reinfection, as these samples contain only a small amount of blood. In a new study, researchers investigated a minimally invasive DBS-based test for monitoring HCV infection in people who inject drugs. The study demonstrated that using DBS samples for HCV RNA detection and genotyping effectively evaluates treatment outcomes and distinguishes between reinfection and treatment failure. These results suggest that it is feasible to decentralize treatment and post-treatment monitoring for people injecting drugs, who may encounter difficulties in accessing healthcare services.

Related Links:
IGTP

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.